Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib: a case report.

Canine cutaneous epitheliotropic T-cell lymphoma (CETL) is associated with a poor prognosis and without consistently beneficial treatment options. This case report describes a 9-year-old Staffordshire bull terrier with CETL treated with oclacitinib (0.7 mg/kg twice daily), resulting in partial remission that was maintained for three months. Further studies are warranted.

[1]  G. Shouse,et al.  Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders , 2019, Current Hematologic Malignancy Reports.

[2]  J. Jaroszewski,et al.  Oclacitinib depletes canine CD4+ and CD8+ T cells in vitro. , 2018, Research in veterinary science.

[3]  G. Inghirami,et al.  Durable Responses Observed with JAK Inhibition in T-Cell Lymphomas , 2018, Blood.

[4]  R. Gogal,et al.  Immunomodulatory in vitro effects of oclacitinib on canine T‐cell proliferation and cytokine production , 2018, Veterinary dermatology.

[5]  A. Moore,et al.  Clinical outcome and prognosis of dogs with histopathological features consistent with epitheliotropic lymphoma: a retrospective study of 148 cases (2003–2015) , 2018, Veterinary dermatology.

[6]  M. Vermeer,et al.  Molecular advances in cutaneous T-cell lymphoma , 2018, Seminars in cutaneous medicine and surgery.

[7]  T. Olivry,et al.  Is CCNU (lomustine) valuable for treatment of cutaneous epitheliotropic lymphoma in dogs? A critically appraised topic , 2016, BMC Veterinary Research.

[8]  J. Boucher,et al.  The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog. , 2014, Journal of veterinary pharmacology and therapeutics.

[9]  A. Gonzales,et al.  Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy , 2014, Journal of veterinary pharmacology and therapeutics.

[10]  R. Mueller,et al.  Canine cutaneous epitheliotropic T-cell lymphoma: a review. , 2009, Veterinary and comparative oncology.